3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
8
NIH
1
NETWORK
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Breast Neoplasms
3
Gliosarcoma
2
Glioblastoma
2
Central Nervous System Neoplasms
2
Breast Neoplasms, Male
2
Waldenstrom Macroglobulinemia
1
Somatostatinoma
1
Sarcoma
1
Rhabdoid Tumor
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Osteosarcoma
1
Mesothelioma, Malignant
1
Meningioma
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Kidney Neoplasms
1
Insulinoma
1
Immunoblastic Lymphadenopathy
1
Glucagonoma
1
Interventions
Ifosfamide
19
Doxorubicin
19
Filgrastim
17
Radiotherapy
13
Vincristine
11
Cyclophosphamide
11
Etoposide
9
Cisplatin
9
Granulocyte Colony-Stimulating Factor
8
Gene Expression Profiling
8
Trabectedin
7
Polymerase Chain Reaction
7
Dactinomycin
6
sargramostim
5
etoposide phosphate
5
Paclitaxel
5
Mesna
5
Chemotherapy, Adjuvant
4
Brachytherapy
4
pegfilgrastim
3
Topotecan
3
Microarray Analysis
3
Irinotecan
3
Immunohistochemistry
3
Imatinib Mesylate
3
Gemcitabine
3
Dexrazoxane
3
Base Sequence
3
olaparib
2
brostallicin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
NETWORK
×
Sarcoma
×
Everolimus
×
Clear all
NCT01804374
2015-06-17
SERIO
Italian Sarcoma Group
Phase 2
Completed
38 enrolled